For example, miR-542-3p expressions are greatly down-regulated in esophageal cancer, and miR-542-3p can inhibit the migration and aggressiveness of esophageal cancer cells by inhibiting OTUB1 expression [17]; in osteosarcoma, miR-542-3p can curb cell proliferative, migrative and aggressive abilities via targeting ILK [18]; in ovarian cancer, miR-542-3p can target CDK14 to inhibit tumorigenesis [19]; in bladder cancer, importantly, miR-542-3p expression is significantly impaired, and this miRNA can inhibit the viability of BC cells [20]. Here, ILK is linked to breast cancer.